Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Amarin ‘Skinny Label’ Suit on Vascepa Against Hikma Dismissed

Jan. 4, 2022, 9:39 PM

Amarin’s patent-infringement suit against generic-drug maker Hikma was dismissed Tuesday by a federal judge who ruled that Hikma’s labeling for a generic version of the drug didn’t infringe a patent for use of the medicine to reduce cardiovascular diseases.

  • Amarin filed the suit over so-called “skinny label” after Hikma launched its copycat
    • Hikma promotes the drug for severe hypertriglyceridemia, which isn’t covered by a patent, and its public statements that its version is a generic alternative to Vascepa “does not expose Hikma to liability,” District Judge Richard Andrews in Wilmington, Delaware, ruled Tuesday
    • Saying the drug can treat hypertriglyceridemia ...